Skeletal muscle tissue adaptation

Skeletal muscle tissue adaptation" is not a specific molecule, receptor, or canonical drug target. Instead, it refers to the broad physiological and molecular processes by which skeletal muscle changes in response to stimuli such as exercise, disuse, aging, or disease. These adaptations include alterations in metabolism (e.g., increased mitochondrial content and oxidative capacity), structural remodeling (e.g., fiber type switching), and changes in gene expression regulated by multiple signaling pathways such as JAK2/STAT3, TGFβ-Smad2/3-ATF4, Hippo/YAP, Ca2+-NFATC1, mTORC1, AMPK and others[2][4][5]. The process involves coordinated action of many proteins and regulatory networks rather than a single molecular entity. Therefore, it is not considered a therapeutic target like an enzyme or receptor but rather an outcome of complex biological signaling cascades[2][4]. Biomarkers for skeletal muscle adaptation may include mitochondrial biogenesis markers (like PGC-1α), myosin heavy chain isoform shifts indicating fiber type transitions, or activation states of key kinases such as AMPK[5]. No direct drugs interact with “skeletal muscle tissue adaptation” itself; instead drugs may modulate upstream pathways that influence these adaptive responses. In summary: - This entry does not correspond to a discrete molecule/receptor but describes a multifaceted biological process. - It should not be classified as a canonical drug target. - If structured data are required for molecules involved in this process (such as PGC-1α or mTORC1), those should be specified individually.